SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs

BACKGROUND: It has been suggested that sodium–glucose cotransporter 2 (SGLT-2) inhibitors reduce the cardiorenal risk in patients with type 2 diabetes (T2D). The purpose of this study is to provide an update of all large cardiovascular outcome trials (CVOTs) with SGLT-2 inhibitors to assess their ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Giugliano, Dario, Longo, Miriam, Scappaticcio, Lorenzo, Bellastella, Giuseppe, Maiorino, Maria Ida, Esposito, Katherine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8680308/
https://www.ncbi.nlm.nih.gov/pubmed/34915880
http://dx.doi.org/10.1186/s12933-021-01430-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8680308/
https://www.ncbi.nlm.nih.gov/pubmed/34915880
http://dx.doi.org/10.1186/s12933-021-01430-3

Ejemplares similares